Abstract

Plasmacytoid dendritic cells (PDC) constitute a small subset of normal bone marrow (BM) cells but have also been shown to be present, sometimes in large numbers, in several hematological malignancies such as acute myeloid leukemia with RUNX1 mutation, chronic myelomonocytic leukemia or, obviously, blastic plasmacytoid dendritic cell neoplasms. These cells have been reported to display somewhat variable immunophenotypic features in different conditions. However, little is known of their plasticity within individual patients. Using an unsupervised clustering tool (FlowSOM) to re-visit flow cytometry results of seven previously analyzed cases of hematological malignancies (6 acute myeloid leukemia and one chronic myelomonocytic leukemia) with a PDC contingent, we report here on the unexpectedly high variability of PDC subsets. Although five of the studied patients harbored a RUNX1 mutation, no consistent feature of PDCs could be disclosed as associated with this variant. Moreover, the one normal single-node small subset of PDC detected in the merged file of six normal BM could be retrieved in the remission BM samples of three successfully treated patients. This study highlights the capacity of unsupervised flow cytometry analysis to delineate cell subsets not detectable with classical supervised tools.

Highlights

  • Acquired mutations of the runt-related transcription factor 1 (RUNX1) gene are found in 5–15% of patients with de novo acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) such as chronic myelomonocytic leukemia (CMML) [1,2]

  • In this series of seven different cases of leukemia, the first striking feature observed after FlowSOM unsupervised analysis is that malignant blastic populations are highly

  • In this series of seven different cases of leukemia, the first striking feature observed after FlowSOM unsupervised analysis is that malignant blastic populations are highly variable from one patient to the other

Read more

Summary

Introduction

Acquired mutations of the runt-related transcription factor 1 (RUNX1) gene are found in 5–15% of patients with de novo acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) such as chronic myelomonocytic leukemia (CMML) [1,2]. In some leukemias with RUNX1mut , mixed-phenotype acute leukemia (MPAL) characteristics can, be present [5], and RUNX1mut has been associated with AML cases with a plasmacytoid dendritic cell (PDC) component [6,7]. RUNX1mut has only seldom been reported in blastic PDC neoplasms (BPDCN) [6,8], while clusters of mature. An association of BPDCN with CMML has been reported [10,11]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call